Table 1.
Description of the different transmembrane peptides and variants used in the present study, together with the simulation times reached for each peptide.
| TNFR variant | Simulation time (μs) | Sequence |
|---|---|---|
| p75—NMR (2mic) | – | 244-MTRGTTDNLIPVYCSILAAVVVGLVAYIAFKRWNSSKQNKQ-284 |
| p75 dimer (SS) | 6.7 | 248-TTDNLIPVYCSILAAVVVGLVAYIAFKRWNSS-279 |
| p75 (SH) | 6.5 | 248-TTDNLIPVYCSILAAVVVGLVAYIAFKRWNSS-279 |
| p75—NMR (2mjo) | – | 244-MTRGTTDNLIPVYASILAAVVVGLVAYIAFKRWNSSKQNKQ-284 |
| p75 (C257A) | 8.6 | 248-TTDNLIPVYASILAAVVVGLVAYIAFKRWNSS-279 |
| Fas—NMR (2na7) | – | 171-RSNLGWLSLLLLPIPLIVWVKRKEVQKT-198 |
| Fas wt | 7.3 | 171-RSNLGWLCLLLLPIPLIVWVKRKE-194 |
| Fas-C178S | 9.1 | 171-RSNLGWLSLLLLPIPLIVWVKRKE-194 |
| Fas-C178R | 7.3 | 171-RSNLGWLRLLLLPIPLIVWVKRKE-194 |
| DR5—NMR (6nhw) | – | 207-MPGSLSGIIIGVTVAAVVLIVAVFVCKSLLWKKVL-241 |
| DR5 wt | 8.6 | 207-SPCSLSGIIIGVTVAAVVLIVAVFVCKSLLWKKVL-241 |
| DR5-A222Y | 8.7 | 207-SPCSLSGIIIGVTVAYVVLIVAVFVCKSLLWKKVL-241 |
| DR5-G217Y | 9.4 | 207-SPCSLSGIIIYVTVAAVVLIVAVFVCKSLLWKKVL-241 |
Bold letters indicate mutated residues.